Compare IBG & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IBG | NCNA |
|---|---|---|
| Founded | 2018 | 1997 |
| Country | Australia | United Kingdom |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8M | 4.0M |
| IPO Year | 2022 | 2017 |
| Metric | IBG | NCNA |
|---|---|---|
| Price | $0.90 | $1.09 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 31.4K | ★ 75.0K |
| Earning Date | 05-12-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.65 | $0.95 |
| 52 Week High | $6.28 | $4.55 |
| Indicator | IBG | NCNA |
|---|---|---|
| Relative Strength Index (RSI) | 55.03 | 43.62 |
| Support Level | $0.76 | $0.95 |
| Resistance Level | $0.96 | $1.40 |
| Average True Range (ATR) | 0.10 | 0.06 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 70.61 | 47.73 |
Innovation Beverage Group Ltd is a developer, manufacturer and exporter of a growing portfolio of 75 formulations across 14 alcoholic and non-alcoholic brands of beverages such as Australian Bitters company. It has two reportable segments: Australia and the United States. The Australia segment mainly consists of its Australian beverage operations and corporate activities, while the United States segment consists of the operations of its United States subsidiaries. Majority of revenue comes from Australia. Its brands are Australian Bitters Company, Bittertales Aromatic, Twisted Shaker Cocktails, Drummerboy Non Alcoholic Spirits, and Wired For Wine.
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States and the United Kingdom.